Canalevia® Would Be the First and Only Treatment for EID in Dogs To Receive Any Type of Approval From FDA SAN FRANCISCO, CA / ACCESSWIRE / May 3, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its ...
"Specifically, our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in ...
SAN FRANCISCO--(BUSINESS WIRE)--Sep. 2, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), an animal health company focused on developing and commercializing first-in-class ...
SAN FRANCISCO, CA / ACCESSWIRE / February 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has completed filing ...
SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced it is ...
“Specifically, our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in ...
SAN FRANCISCO, CA / ACCESSWIRE / March 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") under its Jaguar Animal Health tradename for the veterinary market, today announced that ...
SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced it is ...
The vaccine initially created to combat bacteria-induced diarrhea has recently demonstrated additional benefits, promoting accelerated growth in infant nonhuman primates. “The 160 million people ...
Bob's prompt recovery from intractable diarrhea upon being removed from his troop suggests that asserting his role as alpha-animal constituted a chronic social challenge that may have altered his ...